LEE011 Ribociclib Cyclin Dependent Kinase Inhibitor Cas 1211441-98-3
LEE011 Ribociclib Cyclin Dependent Kinase Inhibitor Cas 1211441-98-3
+ AII PRODUCTS
- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others
Product
|
Size |
Price |
Stock |
Quantity |
|---|---|---|---|
|
Get Quotation Now Add to Cart Bulk Inquiry |
|||
AddThis Sharing Buttons
Share to FacebookFacebookShare to TwitterTwitterShare to PrintPrintShare to EmailEmailShare to PinterestPinterestShare to GmailGmailShare to LinkedInLinkedInShare to Email AppEmail AppShare to TumblrTumblrShare to MoreAddThis
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
|
Product name:LEE011 Ribociclib |
Purity:98% min |
|
CAS NO:1211441-98-3 |
Solubility:DMSO4.4 mg/mL (10.13 mM) |
|
Molecular Formula:C23H30N8O |
Package:Package according to customer requirements |
|
Molecular Weight:434.537 |
Storage:Store at -20℃ |
Quality control
COA
Remarks
Ribociclib Free Base, also known as LEE011, is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. CDK4/6 inhibitor LEE011 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.
Related Products
BMS-265246; LDC000067; SU9516; Purvalanol A; Alvocidib; AZD-5597; Kenpaullone; ON123300; BS-181; JSH-150; Riviciclib
References
[1].VanArsdale T, et al. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment. Clin Cancer Res. 2015 Jul 1;21(13):2905-10.
[2].Rader J, et al. Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.